See more : Headwater Exploration Inc. (HWX.TO) Income Statement Analysis – Financial Results
Complete financial analysis of BioLineRx Ltd. (BLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioLineRx Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Princeton Capital Corporation (PIAC) Income Statement Analysis – Financial Results
- TECO 2030 ASA (TECO.OL) Income Statement Analysis – Financial Results
- Digital Brands Group, Inc. (DBGI) Income Statement Analysis – Financial Results
- PT Diamond Food Indonesia Tbk (DMND.JK) Income Statement Analysis – Financial Results
- GTY Technology Holdings Inc. (GTYH) Income Statement Analysis – Financial Results
BioLineRx Ltd. (BLRX)
About BioLineRx Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.16M | 113.16M | 63.91M | 31.89M |
| Cost of Revenue | 3.69M | 654.00K | 702.00K | 934.00K | 940.00K | 451.00K | 480.68K | 481.89K | 440.89K | 0.00 | 0.00 | 0.00 | 22.62M | 7.21M |
| Gross Profit | 1.11M | -654.00K | -702.00K | -934.00K | -940.00K | -451.00K | -480.68K | -481.89K | -440.89K | 0.00 | 113.16M | 113.16M | 41.29M | 24.69M |
| Gross Profit Ratio | 23.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 64.60% | 77.40% |
| Research & Development | 12.52M | 17.63M | 19.47M | 18.17M | 23.44M | 19.81M | 19.51M | 11.18M | 11.49M | 10.90M | 12.65M | 17.21M | 11.20M | 15.49M |
| General & Administrative | 16.64M | 5.07M | 4.27M | 3.84M | 3.74M | 4.41M | 4.04M | 3.95M | 3.65M | 3.49M | 3.68M | 3.71M | 3.34M | 4.14M |
| Selling & Marketing | 14.59M | 6.46M | 1.00M | 840.00K | 857.00K | 1.36M | 1.69M | 1.35M | 1.00M | 1.46M | 1.18M | 863.77K | 869.15K | 1.30M |
| SG&A | 31.23M | 11.53M | 5.27M | 4.68M | 4.60M | 5.77M | 5.73M | 5.31M | 4.65M | 4.95M | 4.86M | 4.57M | 4.21M | 5.44M |
| Other Expenses | 7.05M | 5.67M | 42.00K | 70.00K | 78.00K | 27.00K | -260.00K | 7.00K | 153.00K | 2.81M | -280.83K | -322.27K | 0.00 | 50.17K |
| Operating Expenses | 50.80M | 29.16M | 24.78M | 22.93M | 28.11M | 25.61M | 25.24M | 16.51M | 16.20M | 15.85M | 17.63M | 21.83M | 15.41M | 20.98M |
| Cost & Expenses | 54.49M | 29.16M | 24.78M | 22.93M | 28.11M | 25.61M | 25.24M | 16.51M | 16.20M | 15.85M | 17.63M | 21.83M | 15.41M | 28.19M |
| Interest Income | 2.01M | 694.00K | 559.00K | 236.00K | 777.00K | 719.00K | 1.17M | 480.00K | 457.00K | 3.28M | 746.59K | 2.36M | 3.34M | 861.33K |
| Interest Expense | 2.17M | 2.16M | 984.00K | 1.47M | 1.83M | 21.00K | 21.00K | 14.00K | 15.00K | 411.67K | 20.67K | 25.96K | 1.12M | 16.63K |
| Depreciation & Amortization | 1.38M | 654.00K | 702.00K | 934.00K | 940.00K | 451.00K | 480.68K | 481.89K | 441.00K | 246.54K | 329.36K | 407.93K | 410.67K | 511.28K |
| EBITDA | -57.06M | -28.50M | -25.35M | -21.99M | -27.17M | -25.15M | -23.83M | -15.34M | -13.94M | -10.79M | -16.70M | -19.38M | -13.59M | 4.21M |
| EBITDA Ratio | -1,188.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14.88% | -18.90% | -23.47% | 20.90% |
| Operating Income | -49.69M | -29.16M | -24.78M | -22.93M | -28.11M | -25.61M | -25.24M | -16.51M | -16.20M | -15.85M | -17.63M | -21.83M | -15.41M | 3.70M |
| Operating Income Ratio | -1,035.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.58% | -19.29% | -24.11% | 11.61% |
| Total Other Income/Expenses | -10.92M | 4.21M | -2.28M | -7.09M | 2.67M | 2.64M | 888.00K | 672.00K | 1.80M | 6.18M | -13.16K | 1.37M | 1.39M | -1.61M |
| Income Before Tax | -60.61M | -24.95M | -27.05M | -30.02M | -25.45M | -22.96M | -24.35M | -15.84M | -14.40M | -10.17M | -17.64M | -20.42M | 61.52M | 2.10M |
| Income Before Tax Ratio | -1,262.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.59% | -18.04% | 96.26% | 6.57% |
| Income Tax Expense | 1.00K | -6.08M | 1.09M | 911.00K | 1.36M | -4.46M | -888.00K | -672.00K | -1.80M | -5.68M | 15.79K | -1.42M | -2.22M | 1.61M |
| Net Income | -60.61M | -18.87M | -28.14M | -30.93M | -26.81M | -18.51M | -24.35M | -15.84M | -14.40M | -10.17M | -17.64M | -20.42M | -13.19M | 2.10M |
| Net Income Ratio | -1,262.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.59% | -18.04% | -20.63% | 6.57% |
| EPS | -0.94 | -0.37 | -0.64 | -1.84 | -2.75 | -2.56 | -4.06 | -4.23 | -4.20 | -4.71 | -11.77 | -18.08 | -16.00 | 2.54 |
| EPS Diluted | -0.94 | -0.37 | -0.64 | -1.84 | -2.75 | -2.56 | -4.06 | -4.23 | -4.20 | -4.71 | -11.77 | -18.08 | -16.00 | 2.54 |
| Weighted Avg Shares Out | 64.22M | 51.60M | 44.20M | 16.86M | 9.76M | 7.24M | 6.00M | 3.74M | 3.43M | 2.16M | 1.50M | 1.13M | 823.91K | 823.41K |
| Weighted Avg Shares Out (Dil) | 64.22M | 51.60M | 44.20M | 16.86M | 9.76M | 7.24M | 6.00M | 3.74M | 3.43M | 2.16M | 1.50M | 1.13M | 823.91K | 830.31K |
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
BioLineRx: Still A Buy, With Some Questions
BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges
BioLineRx Ltd. (BLRX) Q3 2023 Earnings Call Transcript
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023
3 Tech Stocks That Wall Street Loves More Than Nvidia
3 Top Penny Stocks to Make You a Millionaire in 5 Years
Source: https://incomestatements.info
Category: Stock Reports